Paul Thomson

TL;DR: The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.

TL;DR: The identification of T cell specificity and functionality associated with milder disease, highlights the potential importance of including non-spike proteins within future COVID-19 vaccine design.

TL;DR: Memory responses to specific non-spike proteins provides a method to distinguish recent infection from pre-existing immunity in exposed populations using a range of T cell assays that differentially capture immune cell function.

TL;DR: The discovery of isoniazid-specific CD4+ T-cell clones in patients with liver and skin injury suggests that the adaptive immune system is involved in the pathogenesis of both forms of iatrogenic disease.

TL;DR: It is argued that immune regulatory pathways are one key determinant of susceptibility, as expression and activity of these pathways are influenced by disease, environmental and patient factors, and it is currently impossible to predict whether drug exposure will result in a health benefit, hypersensitivity or both.